eligibility_summary
Adults (≥18) with CD19+ NHL (aggressive/indolent), MCL, or CLL/SLL. Prior therapy: aggressive ≥2 lines or early relapse/not ASCT candidate (Burkitt ≥1), indolent ≥2, MCL ≥1, CLL/SLL ≥2 (e.g., BTKi/BCL2i). ECOG 0–2, measurable disease, adequate organs, caregiver support, HBV/HCV/HIV controlled, prior anti‑CD19 requires confirmed CD19. Exclude: pregnancy, active CNS lymphoma, GVHD needing IS, infection, recent stroke/MI/CHF III–IV, recent SCT/CAR‑T, live vaccine, severe allergy, autoimmune/primary ID on IS, other cancer unless low risk.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05702853. Interventions: 1) CD19–CD34t metabolically programmed CAR T cells (biological, autologous cell therapy). Mechanism: patient T cells are engineered with a CAR targeting CD19 on B cells and include a CD34 truncation tag to enable CD34-based selection/purification. Cells are metabolically primed toward a Th1/Th17-like phenotype to enhance cytotoxic function, persistence, and fitness. 2) Lymphodepletion with cyclophosphamide (alkylating agent) and fludarabine (purine analog/antimetabolite) to reduce host lymphocytes and facilitate CAR T expansion. Targets: malignant CD19+ B cells (NHL, CLL/SLL). Pathways/cells engaged: CAR signaling against CD19, T-cell metabolic programming and Th1/Th17 differentiation, pre-infusion lymphodepletion of endogenous lymphocytes. Dose-escalation 1–2 x10^6 CAR+ T cells/kg.